期刊
TISSUE ENGINEERING PART B-REVIEWS
卷 20, 期 6, 页码 655-668出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/ten.teb.2014.0014
关键词
-
类别
资金
- Research Grants from the AO Foundation [S-12-19P]
- National Institutes of Health (NIH) [1 R03 AR062763-01A1, 5 R03 DE021433-02]
Cartilage defects are normally concomitant with posttraumatic inflammation and pose a major challenge in cartilage repair. Due to the avascular nature of cartilage and its inability to surmount an inflammatory response, the cartilage is easily attacked by proinflammatory factors and oxidative stress; if left untreated, osteoarthritis may develop. Suppression of inflammation has always been a crux for cartilage repair. Pharmacological drugs have been successfully applied in cartilage repair; however, they cannot optimally work alone. This review article will summarize current pharmacological drugs and their application in cartilage repair. The development of extracellular matrix-based scaffolds and preconditioned tissue-specific stem cells will be emphasized because both of these tissue engineering components could contribute to an enhanced ability not only for cartilage regeneration but also for anti-inflammation. These strategies could be combined to boost cartilage repair under inflammatory conditions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据